|Day Low/High||92.20 / 93.00|
|52 Wk Low/High||62.55 / 101.28|
5 biotech stocks that could outperform the overall market in 2016.
United Kingdom-based AstraZeneca agreed to acquire a 55% stake in Dutch Acerta Pharma in a $4 billion deal, the company announced on Thursday.
The merged company can become multiple companies.
History indicates pharmaceutical companies with low multiples offer payoffs down the road.
Look for 2015's record run of mergers and acquisitions to continue.
Here is where to find value next year.
The market has strengthened some since my last update. Apple (AAPL) definitely seems to acting better since its earnings report, and is back above some important moving-day averages. Jim Cramer is right about the stock -- it's one you should hold, n...
AbbVie, Teva and Zimmer Biomet posted solid quarters and are upbeat about the road ahead.
In Monday's analysts' actions, one Wall Street firm is weighing in on the Hewlett Packard split and another firm is giving Abbvie (ABBV) a rating and target price boost.
Stocks ended slightly lower Friday, but enjoyed their best monthly gain in four years in October.
Markets are now up slightly in what is one of most listless trading sessions to end a month that I recall lately. Not much moving. As previously noted, AbbVie (ABBV) might be the standout in the S&P 500 today. It's up more than 10% in trading today...
Futures are up as we get less than an hour from the opening bell for October's last trading day. Earnings reports continued to hit fast and furious this morning, as about one third of S&P 500 companies report quarterly numbers this week. Here are th...
For Friday October 30, TheStreet awaits quarterly results from Exxon Mobil (XOM), Chevron (CVX), Phillips 66 (PSX), Anheuser-Busch InBev (BUD), CVS Health (CVS) and AbbVie (ABBV).
The Food and Drug Administration warns of serious liver injury risk with AbbVie's (ABBV) hepatitis C treatments, Viekira Pak and Technivie. The stock is down by more than 12% on the news.
Put cash to work in large-caps that have become cheap in the current market.
I'll continue to add to Amgen, Teva and AbbVie incrementally as recent selloffs seem unwarranted.
One of my favorite topics over the last few quarters has been stock-buyback programs. Companies like Apple (AAPL) have floated cheap debt to fund buyback programs and other things. I get it -- it's far cheaper to offer debt than perhaps deal with re...